Stephens Cuts Health Catalyst (NASDAQ:HCAT) Price Target to $2.00

Health Catalyst (NASDAQ:HCAT) had its price objective cut by investment analysts at Stephens from $3.50 to $2.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Stephens’ target price points to a potential upside of 44.40% from the company’s current price.

Other equities research analysts have also recently issued research reports about the stock. Citigroup dropped their target price on shares of Health Catalyst from $3.25 to $2.75 and set a “neutral” rating for the company in a research report on Friday, January 9th. Stifel Nicolaus decreased their price objective on shares of Health Catalyst from $3.75 to $2.00 and set a “hold” rating on the stock in a research note on Friday. Cantor Fitzgerald dropped their price objective on shares of Health Catalyst from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Friday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Health Catalyst in a research note on Monday, December 29th. Finally, Raymond James Financial set a $3.00 target price on Health Catalyst in a report on Friday. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $3.25.

Health Catalyst Price Performance

NASDAQ:HCAT traded down $0.41 during trading hours on Friday, reaching $1.39. The company had a trading volume of 1,874,049 shares, compared to its average volume of 833,890. The firm has a market capitalization of $97.96 million, a PE ratio of -0.87 and a beta of 1.76. The stock has a 50-day moving average of $2.07 and a two-hundred day moving average of $2.58. Health Catalyst has a one year low of $1.20 and a one year high of $5.06. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.46.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of Health Catalyst during the fourth quarter valued at $25,000. Pilgrim Partners Asia Pte Ltd acquired a new position in Health Catalyst during the 3rd quarter valued at about $39,000. Cresset Asset Management LLC bought a new position in shares of Health Catalyst in the 2nd quarter valued at about $39,000. FNY Investment Advisers LLC acquired a new stake in shares of Health Catalyst during the 3rd quarter worth approximately $45,000. Finally, Focus Partners Wealth bought a new stake in shares of Health Catalyst during the first quarter worth approximately $46,000. Institutional investors own 85.00% of the company’s stock.

Key Health Catalyst News

Here are the key news stories impacting Health Catalyst this week:

• Positive Sentiment: Full‑year revenue and profitability signal — Health Catalyst closed 2025 with $311.1M in total revenue and $41.4M of Adjusted EBITDA, which management cited as evidence of “solid performance” and long‑term positioning. GlobeNewswire Release
• Positive Sentiment: Technical/analyst bullish view — Some market commentators point to a hammer chart pattern and improving earnings‑estimate revisions as a possible short‑term bottom and a reason buyers may step in. Zacks Article
• Neutral Sentiment: Earnings call transcript available for details — The full Q4 2025 earnings call transcript provides management commentary that may clarify strategy and cadence for 2026. Seeking Alpha Transcript
• Neutral Sentiment: Analyst price‑target reset — Stifel cut its price target from $3.75 to $2.00 and set a “hold” rating, reflecting lower near‑term expectations even though the new target still implies upside from current levels. TickerReport / Benzinga
• Negative Sentiment: Q4 EPS missed estimates — Reported EPS of $0.08 missed Zacks’ $0.09 (and other consensus figures of ~$0.10), reducing confidence in near‑term profitability momentum. Zacks Earnings Miss
• Negative Sentiment: Weaker Q1 revenue guidance — Management guided Q1 revenue to $68.0M–$70.0M versus consensus ~ $74.1M and provided limited EPS detail, signaling growth headwinds and driving immediate downward pressure. MarketBeat / Earnings
• Negative Sentiment: Profitability and metrics remain weak — The company reported a negative net margin (~‑34%) and negative ROE, reinforcing investor concern about returning to sustained profitable growth. Press Release / Financials

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.